Literature DB >> 15589214

Expression of EDA+ and EDB+ fibronectin splice variants in bone.

O Kilian1, R Dahse, V Alt, L Zardi, J Rosenhahn, U Exner, A Battmann, R Schnettler, H Kosmehl.   

Abstract

The extracellular matrix component fibronectin (fn) has fundamental functions in cell attachment, differentiation, proliferation, and migration. Isoforms of cellular fibronectin, named EDA+ fibronectin or embryonal EDB+ fibronectin, are generated by alternative splicing of its mRNA precursors. Little is known about the expression of EDA+ and EDB+ fibronectin splice variants in human bone. The aim of this study was to investigate the expression pattern of fibronectin splice variants in bone cell lines and in different human bone tissue samples (mature bone, early stages of fracture healing, hypotrophic nonunion, osteosarcoma). Analysis was done by immunostaining with recombinant and monoclonal antibodies, qualitative RT-PCR and LightCycler-based real-time quantitative RT-PCR assay. In osteoblast and osteosarcoma cell lines, abundant expression of EDA+ and EDB+ fibronectin was found in immunocytochemistry. High transcription levels of both splice variants mRNA were seen in quantitative RT-PCR in osteosarcoma cell lines. In mature bone, EDA+ and EDB+ were not detectable in immunohistochemistry. Transcription of mRNA in both splice variants was absent in these samples. Early stages of fracture healing and osteosarcoma cell samples exhibited extensive staining for EDA+ and EDB+ fibronectin, and high mRNA levels were found. Both osteosarcoma and bone fracture healing tissue expressed high mRNA levels of the fibronectin splice variants independent of benign or malignant behavior. Low level of EDA+ fibronectin mRNA transcription and focal immunohistochemical staining of EDA+ fibronectin was found in hypotrophic nonunions, whereas EDB+ fibronectin was not detected by immunohistochemistry and qualitative or quantitative PCR. EDA+ fibronectin was found in granulation tissue-forming processes in bone independent from bone-forming activity. EDB+ fibronectin was seen only in high-turnover new osteoid-forming processes like early stages of fracture healing and osteosarcoma and was absent in low-turnover processes like mature bone and hypotrophic nonunion. Both EDA+ and EDB+ fibronectin mark active processes in bone without differentiation between malignant or benign activity. In conclusion, EDA+ and EDB+ fibronectin splice variants are strong markers for active fibrogenetic and osteoid-forming processes in human bones.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15589214     DOI: 10.1016/j.bone.2004.08.008

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

Review 1.  Fibronectin: functional character and role in alcoholic liver disease.

Authors:  Razia S Aziz-Seible; Carol A Casey
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process.

Authors:  Leonardo Freire-de-Lima; Kirill Gelfenbeyn; Yao Ding; Ulla Mandel; Henrik Clausen; Kazuko Handa; Sen-Itiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

3.  Fibronectin and beta-catenin act in a regulatory loop in dermal fibroblasts to modulate cutaneous healing.

Authors:  Kirsten A Bielefeld; Saeid Amini-Nik; Heather Whetstone; Raymond Poon; Andrew Youn; Jian Wang; Benjamin A Alman
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

4.  Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin.

Authors:  Magdalena Przybysz; Krzysztof Borysewicz; Iwona Katnik-Prastowska
Journal:  Rheumatol Int       Date:  2009-02-11       Impact factor: 2.631

Review 5.  Biological and molecular profile of fracture non-union tissue: current insights.

Authors:  Michalis Panteli; Ippokratis Pountos; Elena Jones; Peter V Giannoudis
Journal:  J Cell Mol Med       Date:  2015-03-01       Impact factor: 5.310

6.  Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.

Authors:  Bernhard Robl; Sander Martijn Botter; Aleksandar Boro; Daniela Meier; Dario Neri; Bruno Fuchs
Journal:  Transl Oncol       Date:  2017-04-25       Impact factor: 4.243

7.  Adaptation of the group A Streptococcus adhesin Scl1 to bind fibronectin type III repeats within wound-associated extracellular matrix: implications for cancer therapy.

Authors:  Dudley H McNitt; Soo Jeon Choi; Jessica L Allen; River A Hames; Scott A Weed; Livingston Van De Water; Rita Berisio; Slawomir Lukomski
Journal:  Mol Microbiol       Date:  2019-06-12       Impact factor: 3.501

8.  Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.

Authors:  Kai Shi; Sheng-Lin Wang; Bin Shen; Feng-Qiang Yu; Dan-Feng Weng; Jian-Hua Lin
Journal:  World J Surg Oncol       Date:  2019-01-28       Impact factor: 2.754

9.  Quantification of fibronectin 1 (FN1) splice variants, including two novel ones, and analysis of integrins as candidate FN1 receptors in bovine preimplantation embryos.

Authors:  Karen Goossens; Ann Van Soom; Alex Van Zeveren; Herman Favoreel; Luc J Peelman
Journal:  BMC Dev Biol       Date:  2009-01-06       Impact factor: 1.978

Review 10.  The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine.

Authors:  B Eyden
Journal:  J Cell Mol Med       Date:  2007-12-22       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.